Headlines about Teladoc (NYSE:TDOC) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Teladoc earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media coverage about the health services provider an impact score of 44.7433882827429 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the headlines that may have effected Accern’s scoring:
- Teladoc, Inc. (TDOC) CFO Sells $989,700.00 in Stock (americanbankingnews.com)
- Insider Selling: Teladoc, Inc. (TDOC) CEO Sells 100,000 Shares of Stock (americanbankingnews.com)
- Teladoc Adds New Health System Clients, Achieving 2017 Growth in Excess of 100% NYSE:TDOC (menafn.com)
- Teladoc’s (TDOC) “Buy” Rating Reaffirmed at KeyCorp (americanbankingnews.com)
TDOC has been the subject of a number of research reports. Piper Jaffray Companies restated a “buy” rating and issued a $42.00 target price on shares of Teladoc in a research note on Friday, September 29th. KeyCorp reiterated a “buy” rating and issued a $37.00 price objective on shares of Teladoc in a research report on Sunday, September 17th. Zacks Investment Research upgraded Teladoc from a “sell” rating to a “buy” rating and set a $38.00 price objective for the company in a research report on Wednesday, October 4th. SunTrust Banks reiterated a “buy” rating and issued a $40.00 price objective on shares of Teladoc in a research report on Friday, November 3rd. Finally, Canaccord Genuity set a $42.00 price objective on Teladoc and gave the stock a “buy” rating in a research report on Friday, November 17th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $39.17.
Teladoc (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, November 1st. The health services provider reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.25). Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. The firm had revenue of $68.70 million during the quarter, compared to analyst estimates of $67.53 million. During the same quarter in the previous year, the business earned ($0.33) earnings per share. Teladoc’s revenue for the quarter was up 112.0% compared to the same quarter last year. sell-side analysts predict that Teladoc will post -1.57 EPS for the current fiscal year.
In other Teladoc news, CEO Jason N. Gorevic sold 100,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the transaction, the chief executive officer now owns 718,261 shares in the company, valued at $23,695,430.39. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Mark Hirschhorn sold 25,000 shares of the firm’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $31.93, for a total value of $798,250.00. Following the transaction, the vice president now owns 64,987 shares in the company, valued at approximately $2,075,034.91. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 265,000 shares of company stock worth $8,697,400. Company insiders own 4.47% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2017/12/06/teladoc-tdoc-getting-somewhat-positive-media-coverage-study-finds.html.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
What are top analysts saying about Teladoc Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teladoc Inc. and related companies.